Report of Foreign Issuer (6-k)
September 13 2019 - 8:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
September 2019
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On September 13, 2019, Akari Therapeutics,
Plc (the “Company”) issued a press release announcing that the US Food and Drug Administration has granted orphan-drug
designation for nomacopan for the treatment of bullous pemphigoid (BP). A copy of the press release is attached hereto as Exhibit
99.1 and incorporated herein by reference.
The information in
this Form 6-K including the first paragraph of Exhibit 99.1 is hereby incorporated by reference into all effective registration
statements filed by the Company under the Securities Act of 1933.
Exhibit No.
99.1
|
Press Release dated September 13, 2019.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
|
Name:
|
Clive Richardson
|
|
|
|
Chief Executive Officer and
Chief Operating Officer
|
Date: September 13, 2019
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024